The 2-Minute Rule for AZ191
Inside of a scientific situation aiming to target the DYRK1B survival kinase, thinking of these different features are going to be impossible. Hence, we have analyzed a mixture treatment method targeting DYRK1B as well as the mTOR/AKT pathway within a proof-of-basic principle review. Utilizing DYRK1BTomatidine enhances lifespan and healthspan in C.